Elevated ?-GT predicts HCC in hepatitis C patients with sustained response
As reported in the Journal of Hepatology, an elevated baseline ɣ-GT level is the strongest predictor of developing HCC in non-cirrhotic patients with hepatitis C and a sustained virologic response (HR = 6.44), followed by age (HR = 3.68).
SCCA-IgM predicts survival in HCC patients
As reported in the Journal of Gastroenterology & Hepatology, SCCA-IgM levels are elevated in patients with hepatocellular carcinoma (HCC) compared to patients with cirrhosis and healthy controls. Not only does the SCCA-IgM level predict overall and progression-free survival in HCC patients, but the sensitivity of SCCA-IgM in patients with HCC was 2-fold greater than AFP. A decline in SCCA-IgM levels was shown to be associated with response to treatment.
KIT mutations associated with poor prognosis in GISTs
Based on a meta-analysis (18 studies; n=1487) reported in the World Journal of Surgical Oncology, KIT mutations in patients with gastrointestinal stromal tumors (GISTs) are associated with larger tumors (> 5 cm), higher mitotic activity (> 5), more frequent recurrences (OR = 2.06), more frequent metastases (OR = 2.77), and worse 3-year overall survival (OR = 0.47) compared to patients with PDGFRA mutations or wild-type.